Ferric nitrilotriacetate
Based on 1 Customer Validation
Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 16448-54-7
- Formula: C6H6FeNO6
- Molecular Weight:243.96
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Ferric nitrilotriacetate can be used in animal modeling to create renal tumor and diabetes models. After intraperitoneal injection into mice, it deposits heavily in the liver and pancreas[1][2][3][4].
Administration: 1.8-2.7 mg of Fe/kg • ip • once daily, 6 days a week for 12 weeks
Phenotypic Observations: Renal tubular cell tumors develop. The appearance of renal tumors includes solid, cystic, or hemorrhagic forms. Microscopic examination reveals tumor cells with clear, granular, or spindle shapes, forming solid aggregates, papillae, cysts, or glandular patterns.
Administration: 200 mg/rat • ip • once daily, Specifics of the administration method are detailed in the note
Weeks 1-3: 2 mg Fe/kg, once daily;
Weeks 3-6: 6 mg Fe/kg, once daily;
Next 2 months: 10 mg Fe/kg, once daily.
Phenotypic Observations: Mice exhibited diabetic symptoms, including hyperglycemia, glycosuria, ketonemia, and ketonuria.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 16448-54-7
-
Appearance Solid
-
Molecular Weight 243.96
-
Formula C6H6FeNO6
-
Color Light yellow to yellow
-
SMILES
O=C1[O-][Fe+3]([O-]C2=O)([O-]3)[N](C2)(C1)CC3=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Joël Essogo J, et al. Zanthoxylum heitzii Modulates Ferric Nitrilotriacetate-Dependent Oxidative Alterations in Four Vital Organs: An In Vitro Organoprotective Model. Evid Based Complement Alternat Med. 2017;2017:6058150. [Content Brief]
[2]. Inoue S, et al. Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987 Dec 15;47(24 Pt 1):6522-7. [Content Brief]
[3]. Li JL, et al. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 1987 Apr 1;47(7):1867-9. [Content Brief]
[4]. Awai M, et al. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol. 1979 Jun;95(3):663-73. PMID: 377994; [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ferric nitrilotriacetate Related Classifications
HY-145157 Related Classifications
Powered by Bioz